APA (7th ed.) Citation

Xu, C., Zhang, L., Wang, D., Jiang, S., Cao, D., Zhao, Z., . . . Jin, J. (2021). Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer. Nature Publishing Group.

Chicago Style (17th ed.) Citation

Xu, Chuncao, Lei Zhang, Daifei Wang, Shiqin Jiang, Di Cao, Zhongxiang Zhao, Min Huang, and Jing Jin. Lipidomics Reveals That Sustained SREBP-1-dependent Lipogenesis Is a Key Mediator of Gefitinib-acquired Resistance in EGFR-mutant Lung Cancer. Nature Publishing Group, 2021.

MLA (8th ed.) Citation

Xu, Chuncao, et al. Lipidomics Reveals That Sustained SREBP-1-dependent Lipogenesis Is a Key Mediator of Gefitinib-acquired Resistance in EGFR-mutant Lung Cancer. Nature Publishing Group, 2021.